Abstract
Parkinson’s disease (PD) is a neurodegenerative condition characterized by progressive and profound loss of dopaminergic neurons in the substantia nigra pars compacta leading to the formation of eosinophillic, intracytoplamic, proteinacious inclusions termed as lewy bodies. L-dopa remains as a gold standard for the treatment of PD, and is often combined with carbidopa to reduce the dose-limiting side effects. Long-term levodopa treatment is associated with the development of motor fluctuations and peak dose dyskinesias. Dopamine Replacement Therapy (DRT) with dopamine agonists (DAs) (ropinirole and pramipexole) is used to manage complications of L-dopa treatment, however, has been associated with numerous pharmacovigilence reports. The present review attempts to narrate the multiple receptor interaction of DAs followed by the assessment of their side effects during the treatment of PD and possible remedial strategy for selective targeting of dopamine receptors to overcome these affects in therapy of Parkinson's disease.
Keywords: Apomorphine, Bromocriptine, Dopamine Replacement Therapy, Dopamine receptor, Ergolines, Non-ergolines, dyskinesia, L-dopa treatment, serotonin, anti-parkinsonian
Mini-Reviews in Medicinal Chemistry
Title:Plausible Improvements for Selective Targeting of Dopamine Receptors in Therapy of Parkinson’s Disease
Volume: 12 Issue: 14
Author(s): Pratibha Mehta Luthra and J.B. Senthil Kumar
Affiliation:
Keywords: Apomorphine, Bromocriptine, Dopamine Replacement Therapy, Dopamine receptor, Ergolines, Non-ergolines, dyskinesia, L-dopa treatment, serotonin, anti-parkinsonian
Abstract: Parkinson’s disease (PD) is a neurodegenerative condition characterized by progressive and profound loss of dopaminergic neurons in the substantia nigra pars compacta leading to the formation of eosinophillic, intracytoplamic, proteinacious inclusions termed as lewy bodies. L-dopa remains as a gold standard for the treatment of PD, and is often combined with carbidopa to reduce the dose-limiting side effects. Long-term levodopa treatment is associated with the development of motor fluctuations and peak dose dyskinesias. Dopamine Replacement Therapy (DRT) with dopamine agonists (DAs) (ropinirole and pramipexole) is used to manage complications of L-dopa treatment, however, has been associated with numerous pharmacovigilence reports. The present review attempts to narrate the multiple receptor interaction of DAs followed by the assessment of their side effects during the treatment of PD and possible remedial strategy for selective targeting of dopamine receptors to overcome these affects in therapy of Parkinson's disease.
Export Options
About this article
Cite this article as:
Mehta Luthra Pratibha and Senthil Kumar J.B., Plausible Improvements for Selective Targeting of Dopamine Receptors in Therapy of Parkinson’s Disease, Mini-Reviews in Medicinal Chemistry 2012; 12 (14) . https://dx.doi.org/10.2174/138955712803832645
DOI https://dx.doi.org/10.2174/138955712803832645 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Lipoprotein Subfractions, Uric Acid and Cardiovascular Risk in End-Stage Renal Disease (ESRD) Patients
Current Vascular Pharmacology Animal Models for Studying Neointima Formation
Current Vascular Pharmacology Effect of Gender on Main Clinical Chemistry Parameters in Aged Rats
Current Aging Science Editorial (Thematic Issue: Advanced Biomaterial in Clinical Medicine)
Current Medicinal Chemistry Benzothiazole Derivatives: Novel Inhibitors of Methylglyoxal Mediated Glycation of Proteins In Vitro
Medicinal Chemistry Arterial Ischemic Stroke in Neonates and Children: Review and Current Issues
Current Pediatric Reviews Deciphering the Neuroprotective Role of Glucagon-like Peptide-1 Agonists in Diabetic Neuropathy: Current Perspective and Future Directions
Current Protein & Peptide Science Modulation of Neutrophil Function by Hormones
Current Immunology Reviews (Discontinued) Further LDL Cholesterol Lowering Through Targeting PCSK9 for Coronary Artery Disease
Endocrine, Metabolic & Immune Disorders - Drug Targets Multiplexed Fluorescence Imaging of Tumor Biomarkers in Gene Expression and Protein Levels for Personalized and Predictive Medicine
Current Molecular Medicine Matrix Metalloproteinases: Drug Targets for Myocardial Infarction
Current Drug Targets Mutations of the Apolipoprotein A5 Gene with Inherited Hypertriglyceridaemia: Review of the Current Literature
Current Medicinal Chemistry The Importance of Early Diagnosis and Treatment in Peripheral Arterial Disease: Insights from the PARTNERS and REACH Registries
Current Vascular Pharmacology microRNA in Chondrogenesis, Cartilage and Osteoarthritis
Current Rheumatology Reviews Metabolic Therapy of Heart Failure
Current Pharmaceutical Design New Strategies for Managing Anemia of Chronic Kidney Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Intravascular Targeting of a New Anticoagulant Heparin Compound
Cardiovascular & Hematological Disorders-Drug Targets Statins in Stable Angina Pectoris
Current Pharmaceutical Design Supramolecular Chiro-Biomedical Aspect of β-Blockers in Drug Development
Current Drug Targets Assessment and Clinical Relevance of Non-Fasting and Postprandial Triglycerides: An Expert Panel Statement
Current Vascular Pharmacology